Incidence, mortality, and predictive factors of hepatocellular carcinoma in primary biliary cirrhosis

Gastroenterology Research and Practice

Volumn 2013, Issue , 2013, Pages

  Hosonuma, Kenichi ^a   Sato, Ken ^a   Yanagisawa, Masatoshi ^a   Kakizaki, Satoru ^a   Takagi, Hitoshi ^a   Hirato, Junko ^b   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; URSODEOXYCHOLIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASCITES; ASIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; JAUNDICE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIMARY BILIARY CIRRHOSIS; PRURITUS; REVIEW; SEX RATIO; STANDARDIZED INCIDENCE RATIO; STANDARDIZED MORTALITY RATIO; SURVIVAL TIME; UNIVERSITY HOSPITAL; VARICOSIS;

EID: 84875529459     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2013/168012     Document Type: Review

References (35)

1. Howel D., Metcalf J. V., Gray J., Cancer risk in Primary biliary cirrhosis: a study in northern England. Gut 1999 45 5 756 760 (Pubitemid 29492153)
2. Floreani A., Baragiotta A., Baldo V., Hepatic and extrahepatic malignancies in Primary biliary cirrhosis. Hepatology 1999 29 5 1425 1428 (Pubitemid 29211043)
3. Jones D. E., Metcalf J. V., Collier J. D., Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997 26 5 1138 1142 (Pubitemid 27509294)
4. Shibuya A., Tanaka K., Miyakawa H., Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology 2002 35 5 1172 1178 (Pubitemid 34454014)
5. Melia W. M., Johnson P. J., Neuberger J., Zaman S., Portmann B. C., Williams R., Hepatocellular carcinoma in primary biliary cirrhosis: detection by α -fetoprotein estimation. Gastroenterology 1984 87 3 660 663 2-s2.0-0021139741 (Pubitemid 14061421)
6. Nakanuma Y., Terada T., Doishita K., Miwa A., Hepatocellulr carcinoma in primary biliary cirrhosis: an autopsy study. Hepatology 1990 11 6 1010 1016 2-s2.0-0025194734 10.1002/hep.1840110616 (Pubitemid 20221038)
7. Krasner N., Johnson P. J., Portmann B., Hepatocellular carcinoma in primary biliary cirrhosis: report of four cases. Gut 1979 20 3 255 258 (Pubitemid 9166439)
8. Sorensen H. T., Frijs S., Olsen J. H., Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998 28 4 921 925 (Pubitemid 28450250)
9. Nijhawan P. K., Therneau T. M., Dickson E. R., Incidence of cancer in Primary biliary cirrhosis: the Mayo experience. Hepatology 1999 29 5 1396 1398 (Pubitemid 29211039)
10. Loof L., Adami H. O., Sparen P., Danielsson A., Eriksson L. S., Hultcrantz R., Lindgren S., Olsson R., Prytz H., Ryden B. O., Sandberg-Gertzen H., Wallerstedt S., Cancer risk in Primary biliary cirrhosis: a population-based study from Sweden. Hepatology 1994 20 1 101 104 2-s2.0-0028365234 10.1016/0270-9139(94)90140-6 (Pubitemid 24196497)
11. Cavazza A., Caballerí L., Floreani A., Farinati F., Bruguera M., Caroli D., Parés A., Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 2009 50 4 1162 1168 2-s2.0-70350064032 10.1002/hep.23095
12. Scheuer P., Lefkowitch J., Liver Biopsy Interpretation 1994 London, UK WB Saunders
13. Prince M. I., Chetwynd A., Craig W. L., Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004 53 6 865 870 (Pubitemid 38662138)
14. Poupon R. E., Balkau B., Eschwege E., Poupon R., A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. The New England Journal of Medicine 1991 324 22 1548 1554 2-s2.0-0025876404
15. Angulo P., Batts K. P., Therneau T. M., Jorgensen R. A., Dickson E. R., Lindor K. D., Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999 29 3 644 647 2-s2.0-0032979123 (Pubitemid 29109574)
16. Lindor K. D., Jorgensen R. A., Therneau T. M., Malinchoc M., Dickson E. R., Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clinic Proceedings 1997 72 12 1137 1140 2-s2.0-0030663119 (Pubitemid 27528324)
17. Poupon R. E., Lindor K. D., Cauch-Dudek K., Dickson E. R., Poupon R., Heathcote E. J., Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997 113 3 884 890 2-s2.0-0030852495 10.1016/S0016-5085(97)70183-5 (Pubitemid 27381148)
18. Corpechot C., Chazouillères O., Poupon R., Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. Journal of Hepatology 2011 55 6 1361 1367
19. Takeuchi Y., Ikeda F., Fujioka S., Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. Journal of Gastroenterology and Hepatology 2011 26 9 1395 1401
20. Hazzan R., Tur-Kaspa R., Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. Journal of Clinical Gastroenterology 2010 44 5 371 373 2-s2.0-77951726522 10.1097/MCG.0b013e3181c115b3
21. Iwasaki S., Ohira H., Nishiguchi S., Zeniya M., Kaneko S., Onji M., Ishibashi H., Sakaida I., Kuriyama S., Ichida T., Onishi S., Toda G., Tomita E., Shibata M., Watanabe Y., Iwasaki Y., Hirohara J., Nakamura K., Kiyosawa K., Suzuki K., Yasumura S., The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatology Research 2008 38 6 557 564 2-s2.0-43049149045 10.1111/j.1872-034X.2007.00305.x (Pubitemid 351622281)
22. Nakamuta M., Enjoji M., Kotoh K., Shimohashi N., Tanabe Y., Long-term fibrate treatment for PBC. Journal of Gastroenterology 2005 40 5 546 547 2-s2.0-20444432364 10.1007/s00535-004-1583-7 (Pubitemid 40823294)
23. Angulo P., Lindor K. D., Therneau T. M., Jorgensen R. A., Malinchoc M., Kamath P. S., Dickson E. R., Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999 19 2 115 121 2-s2.0-0033061129 (Pubitemid 29139764)
24. Pares A., Caballeria L., Rodes J., Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006 130 3 715 720 (Pubitemid 43374522)
25. Corpechot C., Abenavoli L., Rabahi N., Chrétien Y., Andréani T., Johanet C., Chazouillères O., Poupon R., Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008 48 3 871 877 2-s2.0-51349157245 10.1002/hep.22428
26. Kuiper E. M., Hansen B. E., de Vries R. A., Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009 136 4 1281 1287
27. Kumagi T., Guindi M., Fischer S. E., Arenovich T., Abdalian R., Coltescu C., Heathcote E. J., Hirschfield G. M., Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. American Journal of Gastroenterology 2010 105 10 2186 2194 2-s2.0-77957851364 10.1038/ajg.2010.216
28. Nakano T., Inoue K., Hirohara J., Arita S., Higuchi K., Omata M., Toda G., Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (a-PBC). Hepatology Research 2002 22 4 250 260 2-s2.0-0036254713 10.1016/S1386-6346(01)00148-6 (Pubitemid 34506223)
29. Leuschner U., Primary biliary cirrhosis-presentation and diagnosis. Clinical Liver Disease 2003 7 4 741 758
30. Muto Y., Sato S., Watanabe A., Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology 2005 3 7 705 713 (Pubitemid 40984733)
31. Muto Y., Sato S., Watanabe A., Moriwaki H., Suzuki K., Kato A., Kato M., Nakamura T., Higuchi K., Nishiguchi S., Kumada H., Ohashi Y., Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatology Research 2006 35 3 204 214 2-s2.0-33745727871 10.1016/j.hepres.2006.04.007
32. Kobayashi M., Ikeda K., Arase Y., Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. Journal of Gastroenterology 2008 43 1 63 70 (Pubitemid 351324988)
33. Fukushima H., Miwa Y., Shiraki M., Oral branched-chain amino acid supplementation improves the oxidized/reduced albumin ratio in patients with liver cirrhosis. Hepatology Research 2007 37 9 765 770 (Pubitemid 47054783)
34. Inoue Y., Koizumi A., Wada Y., Risk and protective factors related to mortality from pneumonia among middleaged and elderly community residents: the JACC Study. Journal of Epidemiology 2007 17 6 194 202
35. Van Dam G. M., Gips C. H., Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scandinavian Journal of Gastroenterology 1997 32 1 77 83 2-s2.0-0031022387 (Pubitemid 27026471)